Physician profile
Benjamin M Ensell
NPI 1932540861
$1,266.31
in general payments reported to CMS, 2019-2025
23 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $229 · 2023: $599 · 2024: $158 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,037.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $165.87 | 2022-2024 | Tremfya, Stelara, Remicade |
| Exact Sciences Corporation | $159.03 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $155.20 | 2023-2025 | |
| Ucb, INC. | $145.26 | 2022-2024 | Cimzia |
| Lilly USA, LLC | $106.31 | 2022-2024 | Taltz, Zepbound, Mounjaro |
| Novo Nordisk INC | $96.24 | 2022-2024 | Rybelsus, Ozempic |
| Idorsia Pharmaceuticals US INC | $58.08 | 2023 | Quviviq |
| Pfizer INC. | $53.70 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $43.25 | 2023-2024 | Opsumit, Uptravi |
| Amgen INC. | $35.39 | 2023-2025 | Avsola, Amjevita, Repatha |
| Sandoz INC. | $35.05 | 2023-2024 | Hyrimoz |
| Ars Pharmaceuticals Operations, INC. | $21.51 | 2025 | Neffy |
| Abbott Laboratories | $20.82 | 2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $20.60 | 2023 | Accrufer |
| Boston Scientific Corporation | $18.71 | 2025 | Watchman Flx |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $18.25 | 2025 | Jatenzo |
| Astrazeneca Pharmaceuticals LP | $17.92 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $17.81 | 2023 | Arcalyst |
| Dynavax Technologies Corporation | $17.44 | 2023 | Heplisav-B |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.17 | 2025 | Caplyta |
| Amneal Pharmaceuticals LLC | $16.28 | 2025 | Unithroid |
| Kowa Pharmaceuticals America, INC. | $13.95 | 2023 | Seglentis |
| Phadia US INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Ensell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.